# Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

> **NCT03508570** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Malignant Peritoneal Neoplasm
- Malignant Retroperitoneal Neoplasm
- Metastatic Cervical Carcinoma
- Metastatic Endometrial Carcinoma
- Metastatic Fallopian Tube Carcinoma
- Metastatic Malignant Female Reproductive System Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Primary Peritoneal Carcinoma
- Peritoneal Carcinomatosis
- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Malignant Female Reproductive System Neoplasm
- Platinum-Refractory Ovarian Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Malignant Female Reproductive System Neoplasm
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Cervical Carcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Malignant Female Reproductive System Neoplasm
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Stage IVA Fallopian Tube Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Primary Peritoneal Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Fallopian Tube Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Primary Peritoneal Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacokinetic Study

## Key facts

- **NCT ID:** NCT03508570
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-21
- **Primary completion:** 2024-11-11
- **Final completion:** 2024-11-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03508570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03508570, "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03508570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*